<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048282</url>
  </required_header>
  <id_info>
    <org_study_id>HIVNET/HPTN 055</org_study_id>
    <nct_id>NCT00048282</nct_id>
  </id_info>
  <brief_title>HIV Prevention Preparedness Study</brief_title>
  <official_title>HIV Prevention Preparedness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide researchers with information that will help them&#xD;
      prepare for a future study to test the efficacy of two anti-HIV vaginal gels. This study will&#xD;
      also estimate how likely people living in certain areas are to become infected with HIV and&#xD;
      other infections passed during sex.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to prepare for the implementation of a second study, HPTN 035: A Phase&#xD;
      II/III Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and PRO 2000/5&#xD;
      Gel (P) for the Prevention of HIV Infection in Women. HPTN 035 requires an average HIV&#xD;
      seroincidence rate of 5-6 percent among enrolled participants. The primary objective of the&#xD;
      present study is to estimate the rates of HIV seroincidence among women targeted for&#xD;
      inclusion in HPTN 035.&#xD;
&#xD;
      Women will be enrolled in this study for 6 to 12 months. Study visits will take place&#xD;
      monthly. At each visit, participants will complete a medical/menstrual history and undergo&#xD;
      pregnancy testing. Each quarter, participants will undergo a structured interview about&#xD;
      sexual practices and will receive HIV and STD tests, education, and counseling. Participants&#xD;
      will also undergo a pelvic exam with wet mount testing for bacterial vaginosis, candidiasis,&#xD;
      and trichomoniasis. Colposcopic evaluations will be performed at selected sites. Pap smears&#xD;
      will be performed at sites with the capacity and expertise to prepare and interpret the&#xD;
      smears and provide appropriate follow-up care to participants with abnormal results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>1200</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV Seronegativity</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Sexually active (defined as having had vaginal intercourse at least once in the 3&#xD;
             months prior to screening).&#xD;
&#xD;
          -  HIV-uninfected at screening.&#xD;
&#xD;
          -  Able and willing to provide adequate locator information for study retention purposes.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of adverse reaction to latex.&#xD;
&#xD;
          -  Non-therapeutic injection drug use in the 12 months prior to screening.&#xD;
&#xD;
          -  Vaginal intercourse more than an average of 2 times per day in the 2 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          -  Plans to travel away from the study site for more than 3 consecutive months in the&#xD;
             next 12 months.&#xD;
&#xD;
          -  Plans to relocate away from the study site in the next 12 months.&#xD;
&#xD;
          -  Pregnancy or plans to become pregnant in the next 12 months.&#xD;
&#xD;
          -  Pregnancy within 42 days prior to enrollment.&#xD;
&#xD;
          -  Enrollment in any other study of a vaginally-applied product.&#xD;
&#xD;
          -  Clinically apparent pelvic exam finding involving deep epithelial disruption.&#xD;
&#xD;
          -  Diagnosis with a current STD and/or other reproductive tract infection requiring&#xD;
             treatment.&#xD;
&#xD;
          -  Conditions that would preclude provision of informed consent, make participation in&#xD;
             the study unsafe, complicate interpretation of study outcome data, or otherwise&#xD;
             interfere with achieving the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saidi Kapiga, MD, MPH, SCD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard School of Public Health (HSPH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gita Ramjee, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>South Africa Medical Research Council</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Weiss, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>R.K. Khan Hospital</name>
      <address>
        <city>Chatsworth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Council</name>
      <address>
        <city>Hlabisa</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hlabisa</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Med Ctr</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chililabombwe</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chilenje Clinic, Lusaka, Sambia</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamwala Clinic</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Zambia</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1478</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <results_reference>
    <citation>Kapiga S, Kelly C, Weiss S, Daley T, Peterson L, Leburg C, Ramjee G. Risk factors for incidence of sexually transmitted infections among women in South Africa, Tanzania, and Zambia: results from HPTN 055 study. Sex Transm Dis. 2009 Apr;36(4):199-206. doi: 10.1097/OLQ.0b013e318191ba01.</citation>
    <PMID>19265734</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B; HPTN 055 Study Team. The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):93-100.</citation>
    <PMID>17984760</PMID>
  </results_reference>
  <results_reference>
    <citation>Schreiber CA, Sammel M, Hillier SL, Barnhart KT. A little bit pregnant: modeling how the accurate detection of pregnancy can improve HIV prevention trials. Am J Epidemiol. 2009 Feb 15;169(4):515-21. doi: 10.1093/aje/kwn345. Epub 2008 Dec 18.</citation>
    <PMID>19095756</PMID>
  </results_reference>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>October 29, 2002</study_first_submitted>
  <study_first_submitted_qc>October 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2002</study_first_posted>
  <last_update_submitted>May 13, 2010</last_update_submitted>
  <last_update_submitted_qc>May 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2010</last_update_posted>
  <keyword>Incidence</keyword>
  <keyword>HIV Seroprevalence</keyword>
  <keyword>Vagina</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Administration, Topical</keyword>
  <keyword>Gels</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

